Reference to what was published in the news under “Avigan® Approved for COVID-19 Treatment in Malaysia”, Agility would like to announce that the Malaysian Ministry of Health’s Drug Control Authority has approved Avigan® for use in treatment of COVID-19 patients.

Earlier this year, Global Response Aid (GRA), an affiliate of Agility, and Dr. Reddy’s Laboratories signed an agreement for exclusive global production, distribution and commercialization of the drug with its developer, FujiFilm Toyama Chemical.

 

Agility cannot assess the financial impact at the moment.

 

Sincerely,

Investor Relations Team

Latest Financial News

News

June 15, 2022

Confirmation of Corporate Action Dates

Dear Investor, Agility would like to confirm the corporate action dates as per the template. Agility’s General Assembly meeting has …

News

June 5, 2022

Agility’s New Board Structure

Based on the resolution of Agility’s General Assembly Meeting that was held on May 16, 2022, Agility’s new board structure …

News

June 1, 2022

Supplement Disclosure: Recommended Cash offer for John Menzies

The board of John Menzies PLC has announced that its shareholders have voted to support a recommended cash offer by …

News

May 31, 2022

Agility’s Adjourned Extra Ordinary General Assembly Meeting

Dear Investor, Agility Public Warehousing Company KSCP held its Extra Ordinary General Assembly Meeting on Monday May 30th2022 through electronic …